Presentation on theme: "What is the Optimal Approach to CLL, BR vs. FCR/FR? Michael J. Keating MD Anderson Cancer Center Presented by: Richard R. Furman Weill Cornell Medical."— Presentation transcript:
What is the Optimal Approach to CLL, BR vs. FCR/FR? Michael J. Keating MD Anderson Cancer Center Presented by: Richard R. Furman Weill Cornell Medical College
Bendamustine Bifunctional Antineoplastic Agent Rummel M, J Clin Oncol. 2005;23:3383. ClH 2 C N N N CH 3 CO 2 H Purine-like Benzimidazole Ring Alkylating Group ClH 2 C Available in Germany, 1971-1992 Unique in vitro anti-tumor profile
Long Term Outcomes for FR: CALGB 9712 Months Survival
Chlorambucil vs. Bendamustine in Untreated CLL: Progression-Free Survival Knauf WU. JCO. 2009; 27:4378
GCLLSG CLL2M: BR in Untreated CLL Treatment: Bendamustine 90 mg/m2 days 1,2 (cycles 1-6) Rituximab: 375 mg/m2 (cycle 1) 500 mg/m2 (cycles 2-6) Study Characteristics: 117 patients No age limit (median=64; range 34-78) 73.5% received all 6 cycles Fischer K. JCO 2012; 30:3209.
CLL2M: BR in Untreated CLL: Event Free Survival median EFS = 33.9 months